Brown Aaron P, Wendler David S, Camphausen Kevin A, Miller Franklin G, Citrin Deborah
Radiation Oncology Branch, National Cancer Institute, 10 CRC, B2-3500, Bethesda, MD 20892, USA.
J Clin Oncol. 2008 Aug 20;26(24):3987-94. doi: 10.1200/JCO.2008.16.9896.
Recent development of drugs that target specific pathways in tumors has increased scientific interest in studying drug effects on tumor tissue. As a result, biopsies have become an important part of many early-phase clinical trials. Performing nondiagnostic tumor biopsies raises technical and ethical concerns mostly related to the use of a potentially harmful procedure with no potential benefit to the patient. This issue is complicated by uncertainty about whether performing biopsies in irradiated fields adds significant risk. This article reviews the clinical, scientific, and ethical considerations involved in performing nondiagnostic tumor biopsies in competent adults for research purposes, with a focus on biopsies performed in the setting of therapeutic irradiation.
Clinical trials that performed biopsies during or within 4 months of the completion of radiotherapy were identified with a literature review.
Twenty-nine studies with 2,160 patients were identified. Sixteen of 29 studies reported adverse events (AEs) but did not report active evaluation for biopsy complications. Ten studies did not mention AEs within the study report. At least three studies actively evaluated patients for biopsy complications. Taking this into consideration, 17 (>1%) of 2,160 patients were reported to have biopsy complications, although reporting of AEs was suboptimal in most studies.
Limited data suggest that biopsies can be performed in irradiated tissues without clinically significant excess risk. Ongoing and future trials including nondiagnostic research biopsies should record and report AEs related to this procedure to provide additional data on safety and toxicity.
针对肿瘤特定通路的药物的最新研发增加了研究药物对肿瘤组织作用的科学兴趣。因此,活检已成为许多早期临床试验的重要组成部分。进行非诊断性肿瘤活检引发了技术和伦理方面的担忧,主要涉及使用一种对患者无潜在益处的潜在有害程序。由于在照射野进行活检是否会增加显著风险尚不确定,这个问题变得更加复杂。本文综述了在有行为能力的成年人中为研究目的进行非诊断性肿瘤活检所涉及的临床、科学和伦理考量,重点关注在治疗性放疗背景下进行的活检。
通过文献综述确定在放疗期间或放疗完成后4个月内进行活检的临床试验。
共确定了29项研究,涉及2160名患者。29项研究中的16项报告了不良事件(AE),但未报告对活检并发症的积极评估。10项研究在研究报告中未提及AE。至少有3项研究对患者的活检并发症进行了积极评估。考虑到这一点,2160名患者中有17名(>1%)报告有活检并发症,尽管大多数研究中AE的报告并不理想。
有限的数据表明,在照射组织中进行活检不会带来临床上显著的额外风险。正在进行和未来的包括非诊断性研究活检在内的试验应记录和报告与该程序相关的AE,以提供关于安全性和毒性的更多数据。